Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37

1.

Rapid antidepressant effect of S-ketamine in schizophrenia.

Bartova L, Papageorgiou K, Milenkovic I, Dold M, Weidenauer A, Willeit M, Winkler D, Kasper S.

Eur Neuropsychopharmacol. 2018 Aug;28(8):980-982. doi: 10.1016/j.euroneuro.2018.05.007. Epub 2018 Jul 2.

PMID:
30041987
2.

International Union of Basic and Clinical Pharmacology CIV: The Neurobiology of Treatment-resistant Depression: From Antidepressant Classifications to Novel Pharmacological Targets.

Caraci F, Calabrese F, Molteni R, Bartova L, Dold M, Leggio GM, Fabbri C, Mendlewicz J, Racagni G, Kasper S, Riva MA, Drago F.

Pharmacol Rev. 2018 Jul;70(3):475-504. doi: 10.1124/pr.117.014977.

PMID:
29884653
3.

Major Depression and the Degree of Suicidality: Results of the European Group for the Study of Resistant Depression (GSRD).

Dold M, Bartova L, Fugger G, Kautzky A, Souery D, Mendlewicz J, Papadimitriou GN, Dikeos D, Ferentinos P, Porcelli S, Serretti A, Zohar J, Montgomery S, Kasper S.

Int J Neuropsychopharmacol. 2018 Jun 1;21(6):539-549. doi: 10.1093/ijnp/pyy009.

4.

Comorbid thyroid disease in patients with major depressive disorder - results from the European Group for the Study of Resistant Depression (GSRD).

Fugger G, Dold M, Bartova L, Kautzky A, Souery D, Mendlewicz J, Serretti A, Zohar J, Montgomery S, Frey R, Kasper S.

Eur Neuropsychopharmacol. 2018 Jun;28(6):752-760. doi: 10.1016/j.euroneuro.2018.03.011. Epub 2018 Apr 26.

PMID:
29705022
5.

Clinical correlates of augmentation/combination treatment strategies in major depressive disorder.

Dold M, Bartova L, Mendlewicz J, Souery D, Serretti A, Porcelli S, Zohar J, Montgomery S, Kasper S.

Acta Psychiatr Scand. 2018 May;137(5):401-412. doi: 10.1111/acps.12870. Epub 2018 Feb 28.

6.

Early improvement and response to antidepressant medications in adults with major depressive disorder. Meta-analysis and study of a sample with treatment-resistant depression.

Olgiati P, Serretti A, Souery D, Dold M, Kasper S, Montgomery S, Zohar J, Mendlewicz J.

J Affect Disord. 2018 Feb;227:777-786. doi: 10.1016/j.jad.2017.11.004. Epub 2017 Nov 10.

PMID:
29254066
7.

Refining Prediction in Treatment-Resistant Depression: Results of Machine Learning Analyses in the TRD III Sample.

Kautzky A, Dold M, Bartova L, Spies M, Vanicek T, Souery D, Montgomery S, Mendlewicz J, Zohar J, Fabbri C, Serretti A, Lanzenberger R, Kasper S.

J Clin Psychiatry. 2018 Jan/Feb;79(1). pii: 16m11385. doi: 10.4088/JCP.16m11385.

PMID:
29228516
8.

Low comorbid obsessive-compulsive disorder in patients with major depressive disorder - Findings from a European multicenter study.

Dold M, Bartova L, Souery D, Mendlewicz J, Porcelli S, Serretti A, Zohar J, Montgomery S, Kasper S.

J Affect Disord. 2018 Feb;227:254-259. doi: 10.1016/j.jad.2017.10.033. Epub 2017 Oct 28.

PMID:
29107818
9.

Dose Escalation of Antidepressants in Unipolar Depression: A Meta-Analysis of Double-Blind, Randomized Controlled Trials.

Dold M, Bartova L, Rupprecht R, Kasper S.

Psychother Psychosom. 2017;86(5):283-291. doi: 10.1159/000477770. Epub 2017 Sep 14.

PMID:
28903107
10.

The impact of comorbid post-traumatic stress disorder in patients with major depressive disorder on clinical features, pharmacological treatment strategies, and treatment outcomes - Results from a cross-sectional European multicenter study.

Dold M, Bartova L, Kautzky A, Souery D, Mendlewicz J, Serretti A, Porcelli S, Zohar J, Montgomery S, Kasper S.

Eur Neuropsychopharmacol. 2017 Jul;27(7):625-632. doi: 10.1016/j.euroneuro.2017.05.004. Epub 2017 May 31.

PMID:
28579072
11.

Robust Antidepressant Effect Following Alternating Intravenous Racemic Ketamine and Electroconvulsive Therapy in Treatment-Resistant Depression: A Case Report.

Bartova L, Weidenauer A, Dold M, Naderi-Heiden A, Kasper S, Willeit M, Praschak-Rieder N.

J ECT. 2017 Sep;33(3):e31-e32. doi: 10.1097/YCT.0000000000000421. No abstract available.

PMID:
28520578
12.

Clinical characteristics and treatment outcomes of patients with major depressive disorder and comorbid anxiety disorders - results from a European multicenter study.

Dold M, Bartova L, Souery D, Mendlewicz J, Serretti A, Porcelli S, Zohar J, Montgomery S, Kasper S.

J Psychiatr Res. 2017 Aug;91:1-13. doi: 10.1016/j.jpsychires.2017.02.020. Epub 2017 Feb 27.

PMID:
28284107
13.

Evidence-based pharmacotherapy of treatment-resistant unipolar depression.

Dold M, Kasper S.

Int J Psychiatry Clin Pract. 2017 Mar;21(1):13-23. doi: 10.1080/13651501.2016.1248852. Epub 2016 Nov 16. Review.

PMID:
27848269
14.

Pharmacological treatment strategies in unipolar depression in European tertiary psychiatric treatment centers - A pharmacoepidemiological cross-sectional multicenter study.

Dold M, Kautzky A, Bartova L, Rabl U, Souery D, Mendlewicz J, Porcelli S, Serretti A, Zohar J, Montgomery S, Kasper S.

Eur Neuropsychopharmacol. 2016 Dec;26(12):1960-1971. doi: 10.1016/j.euroneuro.2016.10.005. Epub 2016 Nov 2.

PMID:
27816317
15.

Are all first-generation antipsychotics equally effective in treating schizophrenia? A meta-analysis of randomised, haloperidol-controlled trials.

Dold M, Tardy M, Samara MT, Li C, Kasper S, Leucht S.

World J Biol Psychiatry. 2016 Apr;17(3):210-20. doi: 10.3109/15622975.2015.1083616. Epub 2016 Feb 26.

PMID:
26919194
16.

Efficacy, Acceptability, and Tolerability of Antipsychotics in Treatment-Resistant Schizophrenia: A Network Meta-analysis.

Samara MT, Dold M, Gianatsi M, Nikolakopoulou A, Helfer B, Salanti G, Leucht S.

JAMA Psychiatry. 2016 Mar;73(3):199-210. doi: 10.1001/jamapsychiatry.2015.2955.

17.

Lithium for schizophrenia.

Leucht S, Helfer B, Dold M, Kissling W, McGrath JJ.

Cochrane Database Syst Rev. 2015 Oct 28;(10):CD003834. doi: 10.1002/14651858.CD003834.pub3. Review.

PMID:
26509923
18.

Factors contributing to the increasing placebo response in antidepressant trials.

Kasper S, Dold M.

World Psychiatry. 2015 Oct;14(3):304-6. doi: 10.1002/wps.20245. No abstract available.

19.

Increasing placebo response in antipsychotic trials: a clinical perspective.

Dold M, Kasper S.

Evid Based Ment Health. 2015 Aug;18(3):77-9. doi: 10.1136/eb-2015-102098. Epub 2015 Jun 29.

PMID:
26124311
20.

Dose escalation of antipsychotic drugs in schizophrenia: a meta-analysis of randomized controlled trials.

Dold M, Fugger G, Aigner M, Lanzenberger R, Kasper S.

Schizophr Res. 2015 Aug;166(1-3):187-93. doi: 10.1016/j.schres.2015.04.024. Epub 2015 May 23.

PMID:
26008883
21.
22.

Second-Generation Antipsychotic Drugs in Anorexia Nervosa: A Meta-Analysis of Randomized Controlled Trials.

Dold M, Aigner M, Klabunde M, Treasure J, Kasper S.

Psychother Psychosom. 2015 Feb 21;84(2):110-116. [Epub ahead of print]

PMID:
25722106
23.

Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders.

Dold M, Samara MT, Li C, Tardy M, Leucht S.

Cochrane Database Syst Rev. 2015 Jan 16;1:CD009831. doi: 10.1002/14651858.CD009831.pub2. Review.

PMID:
25592299
24.

Flupenthixol versus low-potency first-generation antipsychotic drugs for schizophrenia.

Tardy M, Dold M, Engel RR, Leucht S.

Cochrane Database Syst Rev. 2014 Sep 1;(9):CD009227. doi: 10.1002/14651858.CD009227.pub2. Review.

PMID:
25177834
25.

Trifluoperazine versus low-potency first-generation antipsychotic drugs for schizophrenia.

Tardy M, Dold M, Engel RR, Leucht S.

Cochrane Database Syst Rev. 2014 Jul 8;(7):CD009396. doi: 10.1002/14651858.CD009396.pub2. Review.

PMID:
25003310
26.

Efficacy of pharmacotherapy and psychotherapy for adult psychiatric disorders: a systematic overview of meta-analyses.

Huhn M, Tardy M, Spineli LM, Kissling W, Förstl H, Pitschel-Walz G, Leucht C, Samara M, Dold M, Davis JM, Leucht S.

JAMA Psychiatry. 2014 Jun;71(6):706-15. doi: 10.1001/jamapsychiatry.2014.112.

PMID:
24789675
27.

Carbamazepine for schizophrenia.

Leucht S, Helfer B, Dold M, Kissling W, McGrath J.

Cochrane Database Syst Rev. 2014 May 2;(5):CD001258. doi: 10.1002/14651858.CD001258.pub3. Review.

PMID:
24789267
28.

Pharmacotherapy of treatment-resistant schizophrenia: a clinical perspective.

Dold M, Leucht S.

Evid Based Ment Health. 2014 May;17(2):33-7. doi: 10.1136/eb-2014-101813. Epub 2014 Apr 8. Review.

PMID:
24713315
29.

Discontinuous patterns of brain activation in the psychotherapy process of obsessive-compulsive disorder: converging results from repeated FMRI and daily self-reports.

Schiepek G, Tominschek I, Heinzel S, Aigner M, Dold M, Unger A, Lenz G, Windischberger C, Moser E, Plöderl M, Lutz J, Meindl T, Zaudig M, Pogarell O, Karch S.

PLoS One. 2013 Aug 15;8(8):e71863. doi: 10.1371/journal.pone.0071863. eCollection 2013.

30.

Benzodiazepine augmentation of antipsychotic drugs in schizophrenia: a meta-analysis and Cochrane review of randomized controlled trials.

Dold M, Li C, Gillies D, Leucht S.

Eur Neuropsychopharmacol. 2013 Sep;23(9):1023-33. doi: 10.1016/j.euroneuro.2013.03.001. Epub 2013 Apr 17. Review.

PMID:
23602690
31.

Benzodiazepines for schizophrenia.

Dold M, Li C, Tardy M, Khorsand V, Gillies D, Leucht S.

Cochrane Database Syst Rev. 2012 Nov 14;11:CD006391. doi: 10.1002/14651858.CD006391.pub2. Review.

PMID:
23152236
32.

Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a meta-analysis of double-blind, randomized, placebo-controlled trials.

Dold M, Aigner M, Lanzenberger R, Kasper S.

Int J Neuropsychopharmacol. 2013 Apr;16(3):557-74. doi: 10.1017/S1461145712000740. Epub 2012 Aug 29. Review.

PMID:
22932229
33.

[Effect of the degree of instability during therapy on the treatment outcome of in-patient psychotherapy of obsessive-compulsive disorder].

Dold M, Demal U, Lenz G, Schiepek G, Aigner M.

Neuropsychiatr. 2012;26(1):23-7. doi: 10.1007/s40211-012-0003-0. Epub 2012 May 13. German.

PMID:
22718419
34.

Putting the efficacy of psychiatric and general medicine medication into perspective: review of meta-analyses.

Leucht S, Hierl S, Kissling W, Dold M, Davis JM.

Br J Psychiatry. 2012 Feb;200(2):97-106. doi: 10.1192/bjp.bp.111.096594. Review.

PMID:
22297588
35.

[Efficacy of antipsychotic augmentation therapy in treatment-resistant obsessive-compulsive disorder: a meta-analysis of double-blind, randomised, placebo-controlled trials].

Dold M, Aigner M, Lanzenberger R, Kasper S.

Fortschr Neurol Psychiatr. 2011 Aug;79(8):453-66. doi: 10.1055/s-0031-1273397. Epub 2011 Aug 1. Review. German.

PMID:
21809258
36.

[Neuroimaging the various symptom dimensions of obsessive-compulsive disorder].

Dold M, Aigner M.

Neuropsychiatr. 2009;23(4):193-205. Review. German.

PMID:
19909691
37.

Delayed allergic response to propofol.

Dold M, Konarzewski WH.

Anaesthesia. 1989 Jun;44(6):533. No abstract available.

Supplemental Content

Support Center